10-Q: Atossa Therapeutics Q1 2026 Results: Increased R&D Spend

Atossa Therapeutics reports a net loss of $9.6 million for Q1 2026, with increased R&D expenses driven by clinical trial activities for its lead candidate, (Z)-endoxifen.

Summary

• Atossa Therapeutics reported a net loss of $9.6 million for the first quarter ended March 31, 2026, compared to a net loss of $6.7 million for the same period in 2025.
• Total operating expenses increased to $9.9 million from $7.4 million, primarily due to a rise in research and development (R&D) expenses.
• R&D expenses grew by 15% to $4.8 million, driven by increased clinical and pre-clinical trial spending for (Z)-endoxifen.
• General and administrative (G&A) expenses rose by 56% to $5.1 million, largely due to higher legal fees associated with patent litigation.
• The company had $31.7 million in cash and cash equivalents as of March 31, 2026, and working capital of $29.2 million.
• Atossa Therapeutics continues to operate on a going concern basis, with substantial doubt raised due to ongoing net losses and negative operating cash flows.
• The company is pursuing multiple indications for its lead drug candidate, (Z)-endoxifen, in oncology and rare diseases, including Duchenne muscular dystrophy and McCune-Albright Syndrome.
• The company effected a 1-for-15 reverse stock split on February 2, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to the increased net loss, higher operating expenses, and the continued substantial doubt regarding the company's ability to continue as a going concern, despite positive clinical trial developments and FDA designations.

Positives

• The company received FDA designations for (Z)-endoxifen for Duchenne muscular dystrophy (DMD) and McCune-Albright Syndrome (MAS), including Rare Pediatric Disease and Orphan Drug designations, which may provide strategic benefits like potential Priority Review Vouchers (PRVs).
• Early data from the Karisma-(Z)-endoxifen study showed significant reduction in mammographic breast density (MBD) with low-dose (Z)-endoxifen.
• The I-SPY 2 study demonstrated good tolerability and biological activity of (Z)-endoxifen, including reductions in Ki-67 and tumor volume, leading to expansion to a higher dose.
• The RECAST study shows feasibility and good tolerability for (Z)-endoxifen in treating low-risk ductal carcinoma in situ (DCIS), potentially allowing patients to avoid surgery.
• The EVANGELINE study showed strong early biologic activity for (Z)-endoxifen in premenopausal women with ER+/HER2- breast cancer.
• The company has a robust patent portfolio with 24 issued patents and numerous pending applications for its proprietary (Z)-endoxifen.
• A settlement agreement was reached with Intas Pharmaceuticals Ltd. to resolve patent litigation, preserving the company's ability to develop and commercialize Z-endoxifen.

Negatives

• The company reported a net loss of $9.6 million for the quarter, an increase from $6.7 million in the prior year period.
• Operating expenses increased by $2.5 million to $9.9 million, driven by higher R&D and G&A costs.
• The company's ability to continue as a going concern is dependent on obtaining adequate capital, and substantial doubt exists.
• Cash and cash equivalents decreased from $41.3 million at the end of 2025 to $31.7 million at the end of Q1 2026.
• Net cash used in operating activities increased significantly to $9.6 million from $6.0 million in the prior year period.
• The company has not yet established an ongoing source of revenue sufficient to cover operating costs.
• The company faces significant legal fees related to ongoing patent litigation, although a settlement was reached.
• There is a potential liability of $1.1 million related to Australian R&D tax rebates due to uncertainty of sustaining the tax position under audit.

Risks

• The company has a history of operating losses and expects to continue incurring losses, raising substantial doubt about its ability to continue as a going concern.
• The company will need to raise substantial additional capital to fund its operations, and there is no assurance that such funds will be available on acceptable terms.
• Products under development may never achieve significant commercial market acceptance or regulatory approval.
• The company is dependent on third-party service providers for critical operational and clinical trial activities, and any failure or delay by these parties could harm the business.
• The company may encounter delays in its clinical trials or may not be able to conduct them in a timely manner.
• Clinical trials may fail to demonstrate the efficacy and safety of product candidates, preventing or delaying regulatory approval.
• The company faces significant competition from other biotechnology and pharmaceutical companies.
• The company's intellectual property may not be adequately protected, and third-party claims of infringement could arise.
• Legislative or regulatory reforms could make it more difficult and costly to obtain regulatory approval and to manufacture, market, and distribute products.
• Disruptions at the FDA and other government agencies could negatively affect the review of regulatory submissions.
• The company's stock price has been and is likely to continue to be volatile.
• The company may be unable to maintain compliance with Nasdaq's continued listing standards.
• The company may be subject to claims that its employees or contractors have wrongfully used or disclosed confidential information of third parties.
• The company's operations could be adversely affected by business disruptions such as natural disasters, pandemics, or geopolitical instability.

Future Outlook

The company expects to continue incurring operating losses for the foreseeable future as it develops its therapeutic programs. Future funding requirements will depend on factors such as manufacturing costs, clinical trial expenses, intellectual property costs, and potential acquisitions. The company anticipates its existing resources may be insufficient to fund operations for the next twelve months, requiring additional capital. The company does not anticipate generating revenue until its pharmaceutical programs are developed, approved, and successfully commercialized.

Management Comments

• Management states that the company's ability to continue as a going concern is dependent on obtaining adequate capital to fund operating losses until it becomes profitable.
• Management plans to obtain additional capital resources through the sale of equity securities and potentially short-term borrowings.
• Management cannot provide assurance that the company will be successful in accomplishing its plans to secure financing and attain profitable operations.
• Management believes that (Z)-endoxifen has potential applications beyond breast cancer, including in gynecological cancers, endocrine resistance driven by ESR1 mutations, and other rare disease indications like DMD and MAS.
• Management believes the FDA designations for (Z)-endoxifen for DMD and MAS provide strategic benefits, including incentives such as potential PRVs.

Industry Context

StockSavvy.ai notes that Atossa Therapeutics operates in the highly competitive biopharmaceutical sector, focusing on oncology and rare diseases. The company's reliance on (Z)-endoxifen as its lead candidate places significant emphasis on the success of its clinical trials and regulatory pathways. The increasing focus on rare pediatric diseases and orphan drug designations reflects a strategic approach to leverage regulatory incentives, such as PRVs, to enhance value.

Comparison to Industry Standards

• The company's net loss of $9.6 million for the quarter is within the range of early-stage biopharmaceutical companies that are heavily investing in R&D without current revenue.
• The increase in R&D expenses to $4.8 million aligns with industry trends for companies advancing drug candidates through Phase 2 clinical trials, such as those conducted by competitors like Veru Inc. or Radius Health.
• The company's cash burn rate of approximately $9.6 million for the quarter is a critical metric for investors in this sector, and its current cash position of $31.7 million suggests a need for further fundraising within the next 12-18 months, a common scenario for companies at this stage.
• The pursuit of FDA designations like Rare Pediatric Disease and Orphan Drug status is a standard strategy in the industry to gain market exclusivity and potential financial incentives, as seen with companies like Sarepta Therapeutics in the rare disease space.

Legal Proceedings

• On April 3, 2025, Intas Pharmaceuticals Ltd. filed Petitions for Post Grant Review (PGR) and Inter Partes Review (IPR) with the USPTO PTAB seeking to invalidate two of the Company's issued patents related to Endoxifen.
• On April 13, 2026, the Company entered into a Settlement Agreement with Intas and Jina Pharmaceuticals, Inc. to resolve these petitions, agreeing to seek termination of the PTAB proceedings.
• The Settlement Agreement preserves the Company's ability to continue developing and commercializing Z-endoxifen base in its principal areas of focus.
• The Company believes other legal proceedings and claims arising in the ordinary course of business do not have a material effect on its financial position.

Stakeholder Impact

• Shareholders may experience dilution if the company raises additional capital through equity offerings.
• Shareholders face continued volatility in the stock price and potential loss of investment due to the company's going concern status and ongoing losses.
• Employees may be impacted by potential future cost-cutting measures if capital raising efforts are unsuccessful.
• Creditors and suppliers may face increased risk due to the company's financial condition and reliance on future financing.

Next Steps

• Expect to receive top-line durability data from the Karisma-(Z)-endoxifen study before the end of the second quarter of 2026.
• Expect to begin receiving data from the expanded I-SPY 2 study arms (combination therapies) in the second half of 2026.
• Intend to pursue Orphan Drug designation for McCune-Albright Syndrome in the first half of 2026.
• Continue to advance (Z)-endoxifen through clinical studies for various indications.
• Continue to seek additional capital resources to fund operations.

Key Dates

Recommendation

Atossa Therapeutics presents a high-risk, high-reward profile. The company has promising clinical data for (Z)-endoxifen and has secured important FDA designations, which could lead to significant value if successful. However, the substantial doubt regarding its ability to continue as a going concern, coupled with increasing losses and the need for significant future capital raises, presents considerable risk. A 'hold' recommendation reflects a balanced view, acknowledging the potential upside while cautioning against the significant financial and operational uncertainties.

Keywords

Atossa Therapeutics, 10-Q, Quarterly Report, Q1 2026, Z-endoxifen, breast cancer, oncology, rare diseases, clinical trials, biopharmaceutical, net loss, R&D expenses, going concern, FDA designations, Duchenne muscular dystrophy, McCune-Albright Syndrome, reverse stock split